Philips acquires Cardiologs to expand its cardiac diagnostics

6 122
Reference pic

DTMT Network

Royal Philips has announced that it has signed an agreement with France-based medical technology company Cardiologes to strengthen its cardiac monitoring and diagnostics business for an undisclosed amount.

Cardiologs will further strengthen Philips’ cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis and reporting services, the announcement said.
The acquisition will help Philip’s cardiac care solutions by enabling it to monitor patients in real-time using artificial intelligence (AI), the announcement added.

Cardiologs’ technology, which has been cleared by the United States Foods and Drug Administration, for detecting irregular heartbeats, accelerates diagnostic reporting, decreases the reporting errors thus empowering doctors to deliver expert cardiac care faster and more efficiently it noted.

“Offering superb clinical insights, as well as automated clinical reporting, Cardiologs’ medical-grade AI technology and data scientists will be a strong addition to our growing portfolio of cardiac solutions for hospital and ambulatory settings,” Roy Jakobs, the Chief Business Leader Connected Care at Royal Philips said.

“Philips’ global footprint can accelerate the availability of Cardiologs’ technology to patients all over the world and further deliver on the quadruple aim of an improved patient care experience, better health outcomes, improved staff experience, and lower cost of care,” he added.

“We are delighted to become part of Philips and continue innovating together to provide solutions that empower clinicians all around the world,” said Yann Fleureau, Co-Founder and CEO of Cardiologs.

“We look forward to the opportunity to expand the business as part of Philips, maintaining vendor neutrality and continuing to work with third party vendors to drive further adoption of digital health solutions globally,” he added.

Cardiologs will join Philips and will expand the company’s continued AI-focused innovation activities together with the company’s R&D lab in Paris, the company announced.

 


0 Comments

  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *

6+3

higlobin

Back to Top